HCPCS code J0740: Cidofovir billing, units and modifiers

Key takeaways

HCPCS code J0740 bills the injection of cidofovir, 375 mg, given by intravenous infusion.

One unit is one 375 mg vial, so divide the milligrams given by 375 and round up.

Medicare Part B pays J0740 at ASP plus 6%, and the rate changes every quarter.

Every Part B line for a single-dose vial needs JW or JZ, or Medicare rejects it.

Practice management software like Pabau centralizes the infusion note, the codes, and the claim documentation before submission.

HCPCS code J0740 covers the injection of cidofovir, 375 mg, an antiviral given by intravenous infusion. One unit is one 375 mg vial, and that single fact drives most J0740 billing decisions. Miscount the units and the claim either underpays or bounces back for review.

Cidofovir costs enough that payers watch these claims closely. Prior authorization, the JW or JZ modifier, and the diagnosis pairing all have to line up.

This guide covers the code details, Medicare payment, ICD-10 pairing, and NDC reporting. It closes with the checks worth running before the claim leaves your system.

J0740 covers one 375 mg dose of cidofovir

J0740 is the HCPCS Level II code for injection, cidofovir, 375 mg. Level II codes cover drugs and supplies that CPT does not describe.

Within that set, the J series covers drugs given by a route other than oral. CMS maintains the code set through the HCPCS Level II program and updates it quarterly.

The descriptor carries the unit, which is where most J0740 errors start. One unit is 375 mg of cidofovir, not one infusion and not one milligram.

Cidofovir treats CMV retinitis in patients with AIDS

Cidofovir, sold as Vistide, is a nucleotide analogue antiviral. The FDA approved it for cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis threatens sight, and without antiviral treatment it can progress to blindness within weeks.

The drug slows viral DNA replication, and it goes in by intravenous infusion. Most doses are given in a physician office or an outpatient infusion center.

Off-label use exists for other CMV manifestations, though coverage there varies by payer and needs clinical justification.

The label also sets conditions that belong in the chart, and payers look for them:

• FDA-approved indication: CMV retinitis in adults with AIDS
• Route: intravenous infusion, never subcutaneous or intramuscular
• Required with each dose: oral probenecid and saline pre-hydration, which reduce kidney toxicity
• Renal monitoring: serum creatinine and urine protein measured before every infusion
• Induction phase: 5 mg/kg once weekly for two weeks
• Maintenance phase: 5 mg/kg every two weeks

Three details decide whether J0740 gets paid

Units, place of service, and modifiers carry most of the weight on a J0740 claim. Get those three right and the rest is documentation. The two sections below take them in the order the claim is built.

Divide the dose by 375 and round up

One unit equals one 375 mg dose, so the unit count follows the milligrams given. Divide the total dose by 375, then round up to the next whole unit.

A 70 kg patient at 5 mg/kg receives 350 mg, which bills as one unit. An 85 kg patient receives 425 mg, which opens a second vial and bills as two. The table below runs that math across a range of body weights.

Record the dose in milligrams in the note, not only the unit count. When a payer asks how two units were justified, the milligrams are the answer.

Every single-dose vial line needs JW or JZ

Cidofovir infusions usually run in POS 11 (office) or POS 22 (outpatient hospital), and the setting changes what Medicare pays. The drug and its administration bill separately. Add CPT code 96365 for the first hour of the infusion, then the add-on codes for any additional hours.

Since July 1, 2023, Part B claims for single-dose vials must carry either JW or JZ. JW reports a discarded amount, and JZ attests that nothing billable was discarded. From October 2023, CMS began rejecting lines that carry neither modifier. Check the CMS guidance on the JZ modifier before you set up a claim template.

One billing unit is the whole 375 mg vial, so a partial vial leaves less than one unit behind. Medicare does not pay a separate JW line for less than a full unit. In practice, that means most J0740 lines carry JZ.

Medicare pays J0740 at ASP plus 6%, and the rate moves quarterly

Medicare Part B pays J0740 under the average sales price (ASP) method.

The allowable works out to ASP plus 6%, which covers the acquisition cost plus a handling margin. CMS recalculates ASP each quarter from manufacturer sales data, so the J0740 rate changes four times a year.

To find the current allowable, search the CMS Physician Fee Schedule lookup tool by HCPCS code. Do not hardcode a dollar amount into a billing template. A rate that was correct in January will be stale by April, and the practice absorbs the difference.

B25.8 plus an eye code proves medical necessity

Every J0740 claim needs a diagnosis that supports the infusion, and CMV retinitis takes two codes rather than one.

B25.8 records the cytomegalovirus infection. A manifestation code from the H32.8- series records the eye involvement. Sequence the infection first, then the manifestation.

Laterality is not optional on the H32.8X codes. The final digit records the eye. In the fifth position, that X is a placeholder rather than a 7th-character extension.

Match that digit to the eye named in the ophthalmology note, and the pairing holds up under review.

Medicaid claims stall without the 11-digit NDC

State Medicaid programs require the national drug code (NDC) on J-code drug claims. Many commercial payers ask for it too, usually for formulary validation. The NDC ties the vial you bought to the J0740 line on the claim.

Report the NDC in the 11-digit 5-4-2 format. On a CMS-1500, it goes in the shaded area of item 24D. Add the unit qualifier that matches the product, plus the quantity administered. Check the number against the carton in front of you, because generic and reference products carry different codes.

Record the NDC, the lot number, and the expiration date when the drug arrives, not when the claim is built. Some states also want a repackaged NDC when the drug comes through a specialty pharmacy. Read your state Medicaid bulletin before the first claim goes out.

Prior authorization happens before the infusion, not after

Most commercial payers require prior authorization (PA) before cidofovir is given, and Medicare Advantage plans increasingly follow the same policy.

Traditional Medicare Part B does not require PA for most Part B drugs. Local coverage determinations can still set documentation rules, so read the ones your contractor publishes.

The worst outcome is a drug already infused with no payment pathway behind it. Verify coverage and secure the authorization before the patient is scheduled, then work through the four steps below.

• Document the indication: PA forms ask for ICD-10 codes, eye exam findings, HIV confirmation, and often a CD4 count
• Re-verify each phase: induction and maintenance can carry different authorization periods
• Track expiration dates: dosing every two weeks spans several billing events
• Appeal with clinical records: attach the letter of medical necessity and the notes showing active retinitis

Run these checks before you submit

A J0740 claim pulls from the chart, the drug record, the payer portal, and the current fee schedule. One short pass across all four catches most first-submission errors. Work down the list while the visit is still fresh.

• The dose in milligrams appears in the note, and the unit count matches it
• The line carries JW or JZ, and only one of the two
• B25.8 and the H32.8X code with the documented laterality are both on the claim
• The authorization is active for this date of service, not only for induction
• The allowable comes from the current quarter rather than last quarter’s fee schedule

Three mistakes account for most J0740 rework. Units get copied from a previous visit after the dose changed. The line goes out with neither modifier, which Medicare rejects outright. Or the authorization lapses between two maintenance infusions.

Each one comes back with a different remark code. Match the denial codes to the cause before anyone reworks the line.

Related J-codes you may see alongside J0740

Billers working with cidofovir usually handle the other CMV antivirals too. The codes below share the same documentation pattern and the same payer scrutiny.

How Pabau keeps the infusion record and the claim together

Most of the detail above lives in two places at once. The infusion note sits in the clinical record, and someone rebuilds the claim somewhere else. That hand-off is where the dose, the diagnosis, and the authorization number drift apart.

Practice management software like Pabau closes that hand-off. Its claims software for practices pre-fills the CMS-1500 from the record itself. The HCPCS code attached to the service lands on the charge line. ICD-10 slots come from the patient’s recorded problem list.

Built-in code libraries let staff search current HCPCS and ICD-10-CM codes without leaving the claim. Pabau also checks that claim-required fields are complete before the send button unlocks.

In the US, claims route through Claim.MD, so eligibility checks, claim status, and remittance posting happen in the same system.

Your team still decides the units and the modifier. What changes is that the documentation behind both stays in one record, ready for submission or an appeal.

Keep J-code documentation and claims in one record

Pabau pre-fills the claim from the clinical record and checks required fields before submission. Claim status and remittances land in the same system, so your team stops rebuilding J0740 claims from scratch.

Book a demo

Conclusion

J0740 rewards a boring, repeatable process. The code itself is simple, and the failures come from the milligrams, the modifier, and the authorization date. Fix that sequence once and the same claim goes out clean every two weeks.

Decide who owns each check, then move it into the infusion visit instead of the billing run. The vial record, the eye exam, and the authorization number are all easier to capture on the day.

Book a demo to see how Pabau keeps that documentation attached to the claim your team submits.

Continue your research

Want every J-code claim submission-ready? Clean claim requirements sets out the payer-agnostic checklist behind first-pass acceptance.

Stuck in repeat denials on high-cost drugs? Denial management in healthcare covers root-cause analysis and the appeal workflow that follows.

Need a prior authorization workflow that holds? The prior authorization process walks through each step, from request to approval and renewal.

Checking coverage before the infusion is booked? Insurance eligibility verification explains what to confirm and when to confirm it.

New to the end-to-end billing process? What is medical billing follows a claim from the encounter through to payment.

Frequently asked questions